Statins Beyond LDL-C: Pleiotropy, Special populations, & Why They Still Matter

About this episode

This episode discusses the broader implications of statins beyond cholesterol reduction, including their pleiotropic effects and considerations for special populations.

Let’s talk about statins. I know… boring, right? Most of us already know a lot about them. But thinking of statins only as cholesterol drugs misses the bigger picture. In many ways, statins are best understood as anti-atherosclerotic therapies that modify plaque biology, vascular inflammation, and cardiovascular risk far beyond simple LDL reduction. In this episode, we cover: Pleiotropic effects of statins beyond LDL-C loweringChoosing the right statin in special populationsWhy statins remain...

People in this episode

Host: Vishnu Priya Pulipati, MD, FACE, DipABCL

Topics covered

• statins
• pleiotropy
• special populations
• cardiovascular health
• cholesterol management

Keywords

• statins
• LDL-C
• pleiotropic effects
• cardiovascular risk
• anti-atherosclerotic
• special populations
• vascular inflammation

Mentioned in this episode

Organizations: LDL-C, anti-atherosclerotic therapies, cardiovascular risk

Products: statins

More episodes of LipidCurious

• A Simple 3-Step Way to Approach the 2026 Multisociety Dyslipidemia (or Any) Guideline · March 27, 2026 · 10 min
• LipidCurious Inspiration: Dr.Thomas Dayspring · February 27, 2026 · 14 min
• ASCVD Risk Stratification Series (Part 3/3): LDL-C Targets, Treatment Options & The Future of Prevention [Pre-2026 Guidelines] · February 13, 2026 · 17 min
• ASCVD Risk Stratification Series (Part 2/3): Using Risk Scores & Enhancers Without Getting Lost in Them [Pre-2026 Guidelines] · January 30, 2026 · 18 min
• ASCVD Risk Stratification Series (Part 1/3): Before the Risk Calculator [Pre-2026 Guidelines] · January 16, 2026 · 16 min
• Looking Ahead: A New Chapter for LipidCurious · January 2, 2026 · 7 min